Adherium Limited (ASX:ADR): When Will It Breakeven?

Adherium Limited (ASX:ADR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Adherium Limited, a digital health company, develops, manufactures, and supplies digital health technologies that address sub-optimal medication use in chronic diseases in New Zealand, Australia, Europe, and North America. The AU$4.7m market-cap company announced a latest loss of AU$14m on 30 June 2026 for its most recent financial year result. Many investors are wondering about the rate at which Adherium will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

According to some industry analysts covering Adherium, breakeven is near. They expect the company to post a final loss in 2027, before turning a profit of AU$5.1m in 2028. Therefore, the company is expected to breakeven roughly 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 108%, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Adherium's growth isn’t the focus of this broad overview, however, take into account that typically a healthcare tech company has lumpy cash flows which are contingent on the product and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Check out our latest analysis for Adherium

Before we wrap up, there’s one issue worth mentioning. Adherium currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are too many aspects of Adherium to cover in one brief article, but the key fundamentals for the company can all be found in one place – Adherium's company page on Simply Wall St. We've also compiled a list of important aspects you should look at:

1. Valuation: What is Adherium worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Adherium is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Adherium’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.